Member Info for KingHomerJ

Beyond Blood are currently Valued at £30million

Development Engineer

Beyond Blood Diagnostics is a fast growing award winning deep-tech start-up focused on leveraging microfluidic technology in combination with semiconductors to monitor vital blood biomarkers critical for cancer patients. Today cancer patients have no visibility on the effectiveness of chemotherapy and with our device they can monitor at home as often as they like the effectiveness of chemotherapy. This position will play a crucial role in bringing our device into patient’s homes and eliminating completely 2 million cancellations every year for the NHS. The company has already secured over £5m in funding over the last 2 years and is committed to developing products that are both safe and effective while navigating complex regulatory environments.

We are seeking a proactive and hands-on Development Engineer to play a crucial role in supporting the product development of our current generation device, from development through to launch. This will also involve contributing to the development of concepts for our next generation of products. The role offers a significant growth opportunity which could lead to truly owning aspects of product development in the longer term. This position is central to ensuring our product meets performance, safety, and regulatory standards as we prepare for patient trials

The collaboration between Physiomics and DoseMeRx in personalized chemotherapy dosing, particularly for docetaxel, presents significant revenue growth opportunities for both companies.

Physiomics' personalized dosing software, initially available on a research basis, is poised to become a paid feature on the DoseMeRx platform. This shift is expected to establish a recurring revenue stream through licensing or subscription models, Integration with DoseMeRx provides Physiomics access to a broader clinical user base across the US and Europe.

The global oncology market is projected to exceed $500 billion by 2030, with a strong emphasis on personalized medicine. This trend underscores the commerciality for Physiomics' personalized dosing solutions.

Laura, the company still has a long way to go to restore market confidence.

however I think a lot of people will be caught offside with this as it only take one piece of News to completely rerate this into the 15-20 million MC it should be - this has happened on numerous shares over the past months / weeks....

There are numerous companies in our sector which have zero revenue - with significant losses into the multi millions, some have one potential assets which are 10-20 times the MC of PYC

PYC has multiple assets and multiple revenue streams and the personalised dossing tool could be worth multi millions alone

numerous contracts to drop

Numerous multi year contracts...

Dosemerx Update and pathway to commercialisation...

Beyond Blood Update...

NHS Trial at Blackpool is halfway through the clinical trial....

Biostatistics Contracts...

People are also forgetting PYC have contracted work signed last December going into 2026 & 2027 (Multi Year Contract)

With the new focus and offering this enables PYC to get multi multi year contracts in all settings across all developments from pre trial to phase 1,2,3,4 and post clinical settings.

With the additional recruitment currently ongoing it would indicate there is a hefty amount of contacts to be annouced

Market Cap is ridiculous with a hefty amount of new contracts to drop....as per the recent company presentation.

Rerate on the Cards

Dosemerx update due any time now - within the next month.

Https://careers.ascpt.org/job/senior-quantitative-pharmacology-modeling-and-simulation-scientist/78379172/?trk=feed_main-feed-card_feed-article-content

Breaks 54 and it’s likley to move very very quickly

Weatherden's involvement has led to substantial value gains for their clients. Repeat and long-term clients have realized over $25 billion in value since partnering with Weatherden. Their input has benefited patient populations worldwide, with an estimated impact exceeding $500 million.

Beyond Blood have recent added a video on LinkedIn

They are discussing they are working at Royce’s - Imperial College London - where they specifically mention the chemotherapy aspect.

This is a huge development….

It’s nothing to worry about as it has zero relevance to PYC….its just regulations that need to be disclosed

The current NHS trial ends in October…..this will be a company maker….

“Physiomics is at the forefront of integrating personalised medicine into NHS oncology care. Through strategic partnerships and government-backed projects, the company is developing tools that tailor chemotherapy dosing to individual patient profiles, thereby improving treatment outcomes and patient safety, the NHS's extensive healthcare network positions Physiomics plc to generate substantial revenue from its precision dosing tool.”

OSD - the timing was in this years finials which are end of June.

DoseMe…..

“The collaboration between Physiomics plc and DoseMeRx has the potential to generate significant revenue, potentially reaching the multi millions of pounds, through integration and licensing.”

Old Share dog,

As per the last investors presentation- the company stated they were in the final stages of 9 contracts in this years financials - one has been announced.

DoseMerx NEWS is IMMINENT

8 contracts due to land before end of June….as per previous investor presentation.

DoseMerx update is imminent….

Physiomics plc is making significant strides in developing and validating its precision dosing software, with the goal of integrating it into NHS clinical practice. The company's alignment with NHS innovation strategies and its active clinical trials suggest a promising trajectory toward adoption, pending successful trial results and evaluations.

The Dosing tool currently in Trial with the NHS Blackpool & Dosemerx is huge for PYC - This trial is due to end in October...

Company Maker......

Estimated Market Size & Tool Value Potential

1. Addressable Market:

o The global precision oncology market is projected to exceed £80 billion by 2030.

o GCSF-related neutropenia management alone represents a multi-billion-dollar submarket within oncology care.

o If Physiomics targets just 1% of high-risk chemotherapy patients in the UK, EU, and US (~1 million annually), and charges:

 £100–£500 per dosing license per patient, the potential annual revenue could be:

 £100M to £500M with adoption.

2. Conservative Valuation Estimate - Based on early-stage rollout and realistic adoption curves:

o Short-term: £500K–£2M revenue potential

o Mid-term £5M–£20M if integrated into mainstream platforms like DoseMeRx, adopted by NHS trusts, or licensed globally

o Exit/Acquisition Scenario: If successful, the tool and IP could attract acquisition interest at multi revenue multiples, yielding a £250M–£500M+ valuation

Value Drivers

• Clinical validation (PREDICT-ONC trial success)

• Integration with EHR and dosing platforms

• Regulatory approvals (NICE, FDA pathways)

• Licensing or subscription model scalability

• Partnership leverage (e.g., with Beyond Blood, DoseMe)

The long-term value of Physiomics plc’s advancements in Antibody-Drug Conjugate (ADC) modelling is very significant, for several reasons:

1. Expansion into a Fast-Growing Market

• ADCs are one of the fastest-growing areas in oncology drug development, with dozens of new ADCs in clinical trials and billions being invested.

• By mastering ADC modelling early, Physiomics has positioned itself as a go-to expert for biotech and pharmaceutical companies developing these therapies.

• This opens doors to bigger and longer-term contracts with clients working on ADCs.

2. Strengthened Competitive Advantage

• Few companies specialize in mathematical modelling for complex therapies like ADCs.

• Physiomics’ expansion of its Virtual Tumour™ platform into ADCs gives it a technical edge that will be hard for competitors to replicate quickly.

• This deepens customer loyalty and increases barriers to entry for rivals.

3. Higher-Value and Longer-Term Projects

• ADC drug development projects tend to run longer and require complex modelling over multiple phases (preclinical → clinical trials → regulatory submissions).

• This should translate into multi-year, high-value contracts for Physiomics, rather than shorter, one-off projects.

4. Improved Financial Stability and Growth Potential

• Broader service offerings = more stable, diversified revenue streams.

• A successful expansion into ADCs could significantly boost revenue growth, profit margins, and eventually market valuation.

5. Strategic Attractiveness for Partnerships or Acquisition

• If Physiomics becomes known for leadership in ADC modelling, it could:

o Attract partnerships with big pharma.

o Become a strategic acquisition target itself for a larger clinical research organization (CRO) or data-driven pharma company.

In 2025, Physiomics plc has made significant strides in Antibody-Drug Conjugate (ADC) modelling, marking a pivotal advancement in oncology drug development.​

Integration of ADCs into the Virtual Tumour Platform

Physiomics expanded its proprietary Virtual Tumour™ platform to incorporate ADCs, a class of targeted cancer therapies that deliver cytotoxic agents directly to tumour cells. This integration allows for enhanced simulation of ADC pharmacokinetics and pharmacodynamics, optimizing dosing strategies and improving therapeutic outcomes. The company's collaboration with a leading pharmaceutical partner on this project underscores its commitment to advancing ADC modelling capabilities .​

New Contract with UK-Based Biotech Firm

In March 2025, Physiomics secured a £102,000 contract with a UK-based biotech company specializing in ADC therapies for hard-to-treat cancers. The project involves developing a pharmacokinetic/pharmacodynamic (PK/PD) model to inform optimal dosing for the client's upcoming first-in-human trial, scheduled between April and August 2025. This collaboration reflects Physiomics' strategic initiative to diversify its client base and expand into new therapeutic modalities .​

physiomics.co.uk

+6

TipRanks

+6

X (formerly Twitter)

+6

Morningstar

+1

TipRanks

+1

FT Markets

+1

TipRanks

+1

Strategic Growth and Industry Positioning

These developments align with Physiomics' broader strategy to broaden its service offerings and solidify its position in the oncology sector. The company's focus on integrating advanced modelling techniques for emerging therapies like ADCs demonstrates its commitment to supporting innovative drug development processes .​

Through these initiatives, Physiomics plc continues to enhance its role in the oncology landscape, providing critical modelling and simulation support for the development of next-generation cancer therapies.

The Beyond Blood Diagnostics and Physiomics tool, once approved, will provide significant value in personalized chemotherapy management, particularly in reducing the risks of chemotherapy-induced neutropenia (CIN).

Value of the Tool When Approved

1. Improved Patient Safety & Outcomes

Helps optimize G-CSF (Granulocyte Colony-Stimulating Factor) dosing, reducing severe neutropenia risks.

Enhances personalized chemotherapy dosing, minimizing side effects and improving treatment success.

2. At-Home Monitoring & Convenience

Patients can use Beyond Blood’s finger-prick blood test at home, reducing hospital visits.

Faster results allow timely interventions for neutropenia, preventing severe infections.

3. Cost Savings for Healthcare Systems (e.g., NHS)

Reduces unnecessary hospital admissions due to neutropenia-related complications.

Minimizes the need for frequent in-hospital blood tests, lowering operational burdens.

4. Enhanced Clinical Decision-Making

Physiomics’ AI-driven software assists oncologists in personalizing treatment plans based on patient-specific blood test results.

o Helps clinicians predict how a patient’s body will respond to chemotherapy.

Who Will Use This Tool?

1. Oncologists & Hematologists

To optimize chemotherapy dosing and prevent severe side effects.

To track patient blood cell counts remotely and adjust treatments accordingly.

2. Cancer Patients Undergoing Chemotherapy

Especially those receiving G-CSF therapy for neutropenia.

Enables self-monitoring at home, reducing hospital visits.

3. Healthcare Providers & NHS Hospitals

NHS and other healthcare institutions will use it to streamline cancer treatment.

Reduces hospital burden by minimizing unnecessary patient visits and emergency interventions.

4. Pharmaceutical & Biotech Companies

Can integrate this tool into clinical trials to enhance chemotherapy effectiveness.

Potential Market Impact

• If approved, the tool could become a standard part of cancer care, adopted widely by healthcare systems like the NHS, private hospitals, and oncology clinics worldwide.

• It may also lead to partnerships with pharmaceutical companies that develop chemotherapy drugs.